Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IBI3005 |
| Synonyms | |
| Therapy Description |
IBI3005 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a camptothecin derivative, which potentially induces cell cycle arrest and apoptosis in tumor cells expressing EGFR and ERBB3 (HER3) (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IBI3005 | IBI-3005|IBI 3005 | EGFR Antibody 73 HER3 (ERBB3) Antibody 28 | IBI3005 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a camptothecin derivative, which potentially induces cell cycle arrest and apoptosis in tumor cells expressing EGFR and ERBB3 (HER3) (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06418061 | Phase I | IBI3005 | Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Recruiting | 1 |